The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology

A. Montero-Luis; C. Aristei; I. Meattini; M. Arenas; L. Boersma; C. Bourgier; C. Coles; B. Cutuli; L. Falcinelli; O. Kaidar-Person; M.C. Leonardi; B. Offersen; F. Marazzi; S. Rivera; L. Tagliaferri; V. Tombolini; C. Vidali; V. Valentini; P. Poortmans

doi:10.1016/j.critrevonc.2019.04.016

The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology

A. Montero-Luis, C. Aristei, I. Meattini, M. Arenas, L. Boersma, C. Bourgier, C. Coles, B. Cutuli, L. Falcinelli, O. Kaidar-Person, M.C. Leonardi, B. Offersen, F. Marazzi, S. Rivera, L. Tagliaferri, V. Tombolini, C. Vidali, V. Valentini, P. Poortmans

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second “Assisi Think Tank Meeting” (ATTM) on Breast Cancer. Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5–20 years work-experience and irradiated 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated. © 2019 Elsevier B.V.

Original language	English
Pages (from-to)	207-213
Number of pages	7
Journal	Crit. Rev. Oncol. Hematol.
Volume	138
DOIs	https://doi.org/10.1016/j.critrevonc.2019.04.016
Publication status	Published - 2019

Keywords

Breast cancer
Ductal carcinoma in situ
Hypofractionation
Post-mastectomy radiotherapy
Survey
estrogen receptor
Ki 67 antigen
progesterone receptor
tamoxifen
age
breast radiotherapy
breast reconstruction
cancer grading
human
hypofractionated radiotherapy
immunohistochemistry
intensity modulated radiation therapy
intraductal carcinoma
mastectomy
nipple sparing mastectomy
postmastectomy radiation therapy
radiation oncologist
Review
skin sparing mastectomy
surgical margin
surgical technique
tomotherapy
tumor volume
adjuvant radiotherapy
breast tumor
female
middle aged
prevention and control
procedures
questionnaire
radiation oncology
risk factor
tumor recurrence
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Dose Fractionation, Radiation
Female
Humans
Mastectomy
Middle Aged
Neoplasm Recurrence, Local
Radiation Oncology
Radiotherapy, Adjuvant
Risk Factors
Surveys and Questionnaires

Access to Document

10.1016/j.critrevonc.2019.04.016

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064612810&doi=10.1016%2fj.critrevonc.2019.04.016&partnerID=40&md5=a1932260a0ac71ae6cd66932aa020c9a

Fingerprint Dive into the research topics of 'The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology'. Together they form a unique fingerprint.

Cite this

Montero-Luis, A., Aristei, C., Meattini, I., Arenas, M., Boersma, L., Bourgier, C., Coles, C., Cutuli, B., Falcinelli, L., Kaidar-Person, O., Leonardi, M. C., Offersen, B., Marazzi, F., Rivera, S., Tagliaferri, L., Tombolini, V., Vidali, C., Valentini, V., & Poortmans, P. (2019). The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology. Crit. Rev. Oncol. Hematol., 138, 207-213. https://doi.org/10.1016/j.critrevonc.2019.04.016

The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice : Critical Reviews in Oncology/Hematology. / Montero-Luis, A.; Aristei, C.; Meattini, I.; Arenas, M.; Boersma, L.; Bourgier, C.; Coles, C.; Cutuli, B.; Falcinelli, L.; Kaidar-Person, O.; Leonardi, M.C.; Offersen, B.; Marazzi, F.; Rivera, S.; Tagliaferri, L.; Tombolini, V.; Vidali, C.; Valentini, V.; Poortmans, P.

In: Crit. Rev. Oncol. Hematol., Vol. 138, 2019, p. 207-213.

Research output: Contribution to journal › Article › peer-review

Montero-Luis, A, Aristei, C, Meattini, I, Arenas, M, Boersma, L, Bourgier, C, Coles, C, Cutuli, B, Falcinelli, L, Kaidar-Person, O, Leonardi, MC, Offersen, B, Marazzi, F, Rivera, S, Tagliaferri, L, Tombolini, V, Vidali, C, Valentini, V & Poortmans, P 2019, 'The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology', Crit. Rev. Oncol. Hematol., vol. 138, pp. 207-213. https://doi.org/10.1016/j.critrevonc.2019.04.016

Montero-Luis, A. ; Aristei, C. ; Meattini, I. ; Arenas, M. ; Boersma, L. ; Bourgier, C. ; Coles, C. ; Cutuli, B. ; Falcinelli, L. ; Kaidar-Person, O. ; Leonardi, M.C. ; Offersen, B. ; Marazzi, F. ; Rivera, S. ; Tagliaferri, L. ; Tombolini, V. ; Vidali, C. ; Valentini, V. ; Poortmans, P. / The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice : Critical Reviews in Oncology/Hematology. In: Crit. Rev. Oncol. Hematol. 2019 ; Vol. 138. pp. 207-213.

@article{6fd22dd5fd134a4b897a2c1b2fe440c3,

title = "The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology",

abstract = "Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second “Assisi Think Tank Meeting” (ATTM) on Breast Cancer. Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5–20 years work-experience and irradiated 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated. {\textcopyright} 2019 Elsevier B.V.",

keywords = "Breast cancer, Ductal carcinoma in situ, Hypofractionation, Post-mastectomy radiotherapy, Survey, estrogen receptor, Ki 67 antigen, progesterone receptor, tamoxifen, age, breast radiotherapy, breast reconstruction, cancer grading, human, hypofractionated radiotherapy, immunohistochemistry, intensity modulated radiation therapy, intraductal carcinoma, mastectomy, nipple sparing mastectomy, postmastectomy radiation therapy, radiation oncologist, Review, skin sparing mastectomy, surgical margin, surgical technique, tomotherapy, tumor volume, adjuvant radiotherapy, breast tumor, female, middle aged, prevention and control, procedures, questionnaire, radiation oncology, risk factor, tumor recurrence, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Dose Fractionation, Radiation, Female, Humans, Mastectomy, Middle Aged, Neoplasm Recurrence, Local, Radiation Oncology, Radiotherapy, Adjuvant, Risk Factors, Surveys and Questionnaires",

author = "A. Montero-Luis and C. Aristei and I. Meattini and M. Arenas and L. Boersma and C. Bourgier and C. Coles and B. Cutuli and L. Falcinelli and O. Kaidar-Person and M.C. Leonardi and B. Offersen and F. Marazzi and S. Rivera and L. Tagliaferri and V. Tombolini and C. Vidali and V. Valentini and P. Poortmans",

note = "Cited By :1 Export Date: 28 February 2020 CODEN: CCRHE Correspondence Address: Montero-Luis, A.; Radiation Oncology, University Hospital HM Sanchinarro, c/O{\~n}a 10, Spain; email: amontero@hmhospitales.com Chemicals/CAS: tamoxifen, 10540-29-1 References: Aristei, C., Kaidar-Person, O., Arenas, M., Coles, C., Offersen, B.V., Bourgier, C., Frezza, G., Poortmans, P.M., The 2016 Assisi Think Tank Meeting on breast cancer: white paper (2016) Breast Cancer Res. Treat., 160 (2), pp. 211-221; Bannani, S., Rouquette, S., Bendavid-Athias, C., Tas, P., Lev{\^e}que, J., The locoregional recurrence post-mastectomy for ductal carcinoma in situ: incidence and risk factors (2015) Breast, 24 (October (5)), pp. 608-612; Carlson, G.W., Page, A., Johnson, E., Nicholson, K., Styblo, T.M., Wood, W.C., Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy (2007) J. Am. Coll. Surg., 204 (May (5)), pp. 1074-1078. , discussion 1078-80; Chadha, M., Portenoy, J., Boolbol, S.K., Gillego, A., Harrison, L.B., Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ? (2012) Int. J. Surg. Oncol., 2012; Chan, L.W., Rabban, J., Hwang, E.S., Bevan, A., Alvarado, M., Ewing, C., Esserman, L., Fowble, B., Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? (2011) Int. J. Radiat. Oncol. Biol. Phys., 80 (May (1)), pp. 25-30; Childs, S.K., Chen, Y.H., Duggan, M.M., Golshan, M., Pochebit, S., Punglia, R.S., Wong, J.S., Bellon, J.R., Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ (2013) Int. J. Radiat. Oncol. Biol. Phys., 85 (March (4)), pp. 948-952; Ciervide, R., Dhage, S., Guth, A., Shapiro, R.L., Axelrod, D.M., Roses, D.F., Formenti, S.C., Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy (2012) Int. J. Radiat. Oncol. Biol. Phys., 83 (June (2)), pp. e159-e164; Clements, K., Dodwell, D., Lawrence, G., Ball, G., Francis, A., Pinder, S., Sawyer, E., Sloane Project Steering Group, Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ (2015) Eur. J. Surg. Oncol., 41 (October (10)), pp. 1406-1410; Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred, N.J., Forbes, J.F., George, W.D., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2011) Lancet Oncol., 12 (January (1)), pp. 21-29; Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred NJ Forbes, J.F., Bishop, H., George, W.D., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2011) Lancet Oncol., 12 (January (1)), pp. 21-29; Donker, M., Liti{\`e}re, S., Werutsky, G., Julien, J.P., Fentiman, I.S., Agresti, R., Rouanet, P., Bijker, N., Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial (2013) J. Clin. Oncol., 31 (November (32)), pp. 4054-4059; Early Breast Cancer Trialists{\textquoteright} Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., Darby, S., Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast (2010) J. Natl. Cancer Inst. Monogr., 2010 (41), pp. 162-177; Elshof, L.E., Schaapveld, M., Schmidt, M.K., Rutgers, E.J., van Leeuwen, F.E., Wesseling, J., Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women (2016) Breast Cancer Res. Treat., 159 (October (3)), pp. 553-563; Fisher, B., Dignam, J., Wolmark, N., Wickerham, D.L., Fisher, E.R., Mamounas, E., Smith, R., Oishi, R.H., Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999) Lancet, 353 (June (9169)), pp. 1993-2000; Fitzsullivan, E., Lari, S.A., Smith, B., Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? (2013) Ann. Surg. Oncol., 20 (13), pp. 4103-4112; Forbes, J.F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., von Minckwitz, G., IBIS-II investigators, Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial (2016) Lancet, 387 (February (10021)), pp. 866-873; Ganz, P.A., Cecchini, R.S., Julian, T.B., Margolese, R.G., Costantino, J.P., Vallow, L.A., Albain, K.S., Wolmark, N., Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) Lancet, 387 (February (10021)), pp. 857-865; Giannakeas, V., Sopik, V., Narod, S.A., Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy (2018) JAMA Netw. Open, 1 (4); Hathout, L., Hijal, T., Th{\'e}berge, V., Fortin, B., Vulpe, H., Hogue, J.C., Lambert, C., Yassa, M., Hypofractionated radiation therapy for breast ductal carcinoma in situ (2013) Int. J. Radiat. Oncol. Biol. Phys., 87 (December (5)), pp. 1058-1063; Isfahanian, N., Al-Hajri, T., Marginean, H., Chang, L., Caudrelier, J.M., Hypofractionation is an acceptable alternative to conventional fractionation in the treatment of postlumpectomy ductal carcinoma in situ with radiotherapy (2017) Clin. Breast Cancer, 17 (April (2)), pp. e77-e85; Jensen, M.B., Laenkholm, A.V., Offersen, B.V., Christiansen, P., Kroman, N., Mouridsen, H.T., Ejlertsen, B., The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016 (2018) Acta Oncol., 57 (1), pp. 13-18; Jones, C.E., Richman, J., Jackson, B.E., Wallace, A.S., Krontiras, H., Urist, M.M., Bland, K.I., Parker, C.C., Treatment patterns for ductal carcinoma in situ with close or positive mastectomy margins (2018) J. Surg. Res., 231 (November), pp. 36-42; Karavites, L.C., Kane, A.K., Zaveri, S., Xu, Y., Helenowski, I., Hansen, N., Bethke, K.P., Khan, S.A., Tamoxifen acceptance and adherence among patients with ductal carcinoma in situ (DCIS) treated in a multidisciplinary setting (2017) Cancer Prev. Res. (Phila.), 10 (July (7)), pp. 389-397; Kelley, L., Silverstein, M., Guerra, L., Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index (2011) Ann. Surg. Oncol., 18 (February (2)), pp. 459-462; Klein, J., Kong, I., Paszat, L., Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis (2015) SpringerPlus, 4, p. 335. , Published 2015 Jul 10; Lalani, N., Paszat, L., Sutradhar, R., Thiruchelvam, D., Nofech-Mozes, S., Hanna, W., Slodkowska, E., Rakovitch, E., Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast (2014) Int. J. Radiat. Oncol. Biol. Phys., 90 (December (5)), pp. 1017-1024; Mallon, P.T., McIntosh, S.A., Post mastectomy radiotherapy in breast cancer: a survey of current United Kingdom practice (2012) J. BUON, 17 (April-June (2)), pp. 245-248; Margolese, R.G., Cecchini, R.S., Julian, T.B., Ganz, P.A., Costantino, J.P., Vallow, L.A., Albain, K.S., Wolmark, N., Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) Lancet, 387 (February (10021)), pp. 849-856; McCormick, B., Randomized trial evaluating radiation following surgical excision for “good risk” DCIS: 12-year report from NRG/ RTOG 9804 2018 ASTRO Annual Meeting Late-breaking Abstract Selection (2019) Int. J. Radiat. Oncol. Biol. Phys., 102 (November (3) (Supplement)); McCormick, B., Winter, K., Hudis, C., Kuerer, H.M., Rakovitch, E., Smith, B.L., Sneige, N., White, J., RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation (2015) J. Clin. Oncol., 33 (March (7)), pp. 709-715; Meattini, I., Lambertini, M., Isacco, D., De Caluw{\'e}, A., Kaidar-Person, O., Lorenzo, L.L., Radiation therapy for young women with early breast cancer: current state of the art (2019) Crit. Rev. Oncol. Hematol., p. 137; Montero, A., Sanz, X., Hernanz, R., Cabrera, D., Arenas, M., Bayo, E., Moreno, F., Algara, M., Accelerated hypofractionated breast radiotherapy: FAQs (frequently asked questions) and facts (2014) Breast, 23 (August (4)), pp. 299-309; Pesce, C.E., Liederbach, E., Czechura, T., Winchester, D.J., Yao, K., Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base (2014) J. Am. Coll. Surg., 219 (July (1)), pp. 19-28; Rakovitch, E., Nofech-Mozes, S., Hanna, W., Sutradhar, R., Gu, S., Fong, C., Tuck, A., Paszat, L., Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy (2018) Breast, 37 (February), pp. 181-186; Rashtian, A., Iganej, S., Amy Liu, I.L., Natarajan, S., Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy (2008) Int. J. Radiat. Oncol. Biol. Phys., 72 (November (4)), pp. 1016-1020; Rutter, C.E., Park, H.S., Killelea, B.K., Evans, S.B., Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the United States (2015) Ann. Surg. Oncol., 22 (July (7)), pp. 2378-2386; Shah, C., Vicini, F.A., Berry, S., Julian, T.B., Wilkinson, J.B., Shaitelman, S.F., Khan, A., Goldstein, N., Ductal carcinoma in situ of the breast: evaluating the role of radiation therapy in the management and attempts to identify low-risk patients (2015) Am. J. Clin. Oncol., 38 (October (5)), pp. 526-533; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2018 (2018) CA Cancer J. Clin., 68 (Jane (1)), pp. 7-30; Solin, L.J., Gray, R., Hughes, L.L., Wood, W.C., Lowen, M.A., Badve, S.S., Baehner, F.L., Davidson, N.E., Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study (2015) J. Clin. Oncol., 33 (November (33)), pp. 3938-3944; Staley, H., McCallum, I., Bruce, J., Postoperative tamoxifen for ductal carcinoma in situ: cochrane systematic review and meta-analysis (2014) Breast, 23 (October (5)), pp. 546-551; START Trialists{\textquoteright} Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Bentzen, S.M., Yarnold, J.R., The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial (2008) Lancet, 371 (March (9618)), pp. 1098-1107; START Trialists{\textquoteright} Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Bliss, J.M., Yarnold, J.R., The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial (2008) Lancet Oncol., 9 (April (4)), pp. 331-341; Strach, M.C., Prasanna, T., Kirova, Y.M., Alran, S., O'Toole, S., Beith, J.M., Poortmans, P., Carroll, S., Optimise not compromise: the importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery (2019) Crit. Rev. Oncol. Hematol., 134 (February), pp. 10-21; Timbrell, S., Al-Himdani, S., Shaw, O., Tan, K., Morris, J., Bundred, N., Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with ductal carcinoma in situ (2017) Ann. Surg. Oncol., 24 (April (4)), pp. 1071-1076; Tsang, Y., Haviland, J., Venables, K., Yarnold, J., FTM Group, The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy (2012) Radiother. Oncol., 104, pp. 143-147; Vargas, C., Kestin, L., Go, N., Krauss, D., Chen, P., Goldstein, N., Martinez, A., Vicini, F.A., Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy (2005) Int. J. Radiat. Oncol. Biol. Phys., 63 (December (5)), pp. 1514-1521; Wai, E.S., Lesperance, M.L., Alexander, C.S., Truong, P.T., Culp, M., Moccia, P., Lindquist, J.F., Olivotto, I.A., Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ (2011) Cancer, 117 (January (1)), pp. 54-62; Wapnir, I.L., Dignam, J.J., Fisher, B., Mamounas, E.P., Anderson, S.J., Julian, T.B., Land, S.R., Wolmark, N., Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS (2011) J. Natl. Cancer Inst., 103 (March (6)), pp. 478-488; W{\"a}rnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., Ringberg, A., Holmberg, L., Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial (2014) J. Clin. Oncol., 32 (November (32)), pp. 3613-3618; Whelan, T.J., Pignol, J.P., Levine, M.N., Julian, J.A., MacKenzie, R., Parpia, S., Shelley, W., Freeman, C., Long-term results of hypofractionated radiation therapy for breast cancer (2010) N. Engl. J. Med., 362 (February (6)), pp. 513-520; Williamson, D., Dinniwell, R., Fung, S., Pintilie, M., Done, S.J., Fyles, A.W., Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ (2010) Radiother. Oncol., 95 (June (3)), pp. 317-320. , doi: 0.1016/j.radonc.2010.03.021; Zhao, H., Hei, N., Wu, Y., Chan, W., Lei, X., Cameron, C., Chang, S., Giordano, S.H., Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ (2017) Cancer, 123 (May (6)), pp. 940-947",

year = "2019",

doi = "10.1016/j.critrevonc.2019.04.016",

language = "English",

volume = "138",

pages = "207--213",

journal = "Crit. Rev. Oncol. Hematol.",

issn = "1879-0461",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice

T2 - Critical Reviews in Oncology/Hematology

AU - Montero-Luis, A.

AU - Aristei, C.

AU - Meattini, I.

AU - Arenas, M.

AU - Boersma, L.

AU - Bourgier, C.

AU - Coles, C.

AU - Cutuli, B.

AU - Falcinelli, L.

AU - Kaidar-Person, O.

AU - Leonardi, M.C.

AU - Offersen, B.

AU - Marazzi, F.

AU - Rivera, S.

AU - Tagliaferri, L.

AU - Tombolini, V.

AU - Vidali, C.

AU - Valentini, V.

AU - Poortmans, P.

N1 - Cited By :1 Export Date: 28 February 2020 CODEN: CCRHE Correspondence Address: Montero-Luis, A.; Radiation Oncology, University Hospital HM Sanchinarro, c/Oña 10, Spain; email: amontero@hmhospitales.com Chemicals/CAS: tamoxifen, 10540-29-1 References: Aristei, C., Kaidar-Person, O., Arenas, M., Coles, C., Offersen, B.V., Bourgier, C., Frezza, G., Poortmans, P.M., The 2016 Assisi Think Tank Meeting on breast cancer: white paper (2016) Breast Cancer Res. Treat., 160 (2), pp. 211-221; Bannani, S., Rouquette, S., Bendavid-Athias, C., Tas, P., Levêque, J., The locoregional recurrence post-mastectomy for ductal carcinoma in situ: incidence and risk factors (2015) Breast, 24 (October (5)), pp. 608-612; Carlson, G.W., Page, A., Johnson, E., Nicholson, K., Styblo, T.M., Wood, W.C., Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy (2007) J. Am. Coll. Surg., 204 (May (5)), pp. 1074-1078. , discussion 1078-80; Chadha, M., Portenoy, J., Boolbol, S.K., Gillego, A., Harrison, L.B., Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ? (2012) Int. J. Surg. Oncol., 2012; Chan, L.W., Rabban, J., Hwang, E.S., Bevan, A., Alvarado, M., Ewing, C., Esserman, L., Fowble, B., Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? (2011) Int. J. Radiat. Oncol. Biol. Phys., 80 (May (1)), pp. 25-30; Childs, S.K., Chen, Y.H., Duggan, M.M., Golshan, M., Pochebit, S., Punglia, R.S., Wong, J.S., Bellon, J.R., Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ (2013) Int. J. Radiat. Oncol. Biol. Phys., 85 (March (4)), pp. 948-952; Ciervide, R., Dhage, S., Guth, A., Shapiro, R.L., Axelrod, D.M., Roses, D.F., Formenti, S.C., Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy (2012) Int. J. Radiat. Oncol. Biol. Phys., 83 (June (2)), pp. e159-e164; Clements, K., Dodwell, D., Lawrence, G., Ball, G., Francis, A., Pinder, S., Sawyer, E., Sloane Project Steering Group, Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ (2015) Eur. J. Surg. Oncol., 41 (October (10)), pp. 1406-1410; Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred, N.J., Forbes, J.F., George, W.D., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2011) Lancet Oncol., 12 (January (1)), pp. 21-29; Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred NJ Forbes, J.F., Bishop, H., George, W.D., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2011) Lancet Oncol., 12 (January (1)), pp. 21-29; Donker, M., Litière, S., Werutsky, G., Julien, J.P., Fentiman, I.S., Agresti, R., Rouanet, P., Bijker, N., Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial (2013) J. Clin. Oncol., 31 (November (32)), pp. 4054-4059; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., Darby, S., Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast (2010) J. Natl. Cancer Inst. Monogr., 2010 (41), pp. 162-177; Elshof, L.E., Schaapveld, M., Schmidt, M.K., Rutgers, E.J., van Leeuwen, F.E., Wesseling, J., Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women (2016) Breast Cancer Res. Treat., 159 (October (3)), pp. 553-563; Fisher, B., Dignam, J., Wolmark, N., Wickerham, D.L., Fisher, E.R., Mamounas, E., Smith, R., Oishi, R.H., Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999) Lancet, 353 (June (9169)), pp. 1993-2000; Fitzsullivan, E., Lari, S.A., Smith, B., Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? (2013) Ann. Surg. Oncol., 20 (13), pp. 4103-4112; Forbes, J.F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., von Minckwitz, G., IBIS-II investigators, Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial (2016) Lancet, 387 (February (10021)), pp. 866-873; Ganz, P.A., Cecchini, R.S., Julian, T.B., Margolese, R.G., Costantino, J.P., Vallow, L.A., Albain, K.S., Wolmark, N., Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) Lancet, 387 (February (10021)), pp. 857-865; Giannakeas, V., Sopik, V., Narod, S.A., Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy (2018) JAMA Netw. Open, 1 (4); Hathout, L., Hijal, T., Théberge, V., Fortin, B., Vulpe, H., Hogue, J.C., Lambert, C., Yassa, M., Hypofractionated radiation therapy for breast ductal carcinoma in situ (2013) Int. J. Radiat. Oncol. Biol. Phys., 87 (December (5)), pp. 1058-1063; Isfahanian, N., Al-Hajri, T., Marginean, H., Chang, L., Caudrelier, J.M., Hypofractionation is an acceptable alternative to conventional fractionation in the treatment of postlumpectomy ductal carcinoma in situ with radiotherapy (2017) Clin. Breast Cancer, 17 (April (2)), pp. e77-e85; Jensen, M.B., Laenkholm, A.V., Offersen, B.V., Christiansen, P., Kroman, N., Mouridsen, H.T., Ejlertsen, B., The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016 (2018) Acta Oncol., 57 (1), pp. 13-18; Jones, C.E., Richman, J., Jackson, B.E., Wallace, A.S., Krontiras, H., Urist, M.M., Bland, K.I., Parker, C.C., Treatment patterns for ductal carcinoma in situ with close or positive mastectomy margins (2018) J. Surg. Res., 231 (November), pp. 36-42; Karavites, L.C., Kane, A.K., Zaveri, S., Xu, Y., Helenowski, I., Hansen, N., Bethke, K.P., Khan, S.A., Tamoxifen acceptance and adherence among patients with ductal carcinoma in situ (DCIS) treated in a multidisciplinary setting (2017) Cancer Prev. Res. (Phila.), 10 (July (7)), pp. 389-397; Kelley, L., Silverstein, M., Guerra, L., Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index (2011) Ann. Surg. Oncol., 18 (February (2)), pp. 459-462; Klein, J., Kong, I., Paszat, L., Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis (2015) SpringerPlus, 4, p. 335. , Published 2015 Jul 10; Lalani, N., Paszat, L., Sutradhar, R., Thiruchelvam, D., Nofech-Mozes, S., Hanna, W., Slodkowska, E., Rakovitch, E., Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast (2014) Int. J. Radiat. Oncol. Biol. Phys., 90 (December (5)), pp. 1017-1024; Mallon, P.T., McIntosh, S.A., Post mastectomy radiotherapy in breast cancer: a survey of current United Kingdom practice (2012) J. BUON, 17 (April-June (2)), pp. 245-248; Margolese, R.G., Cecchini, R.S., Julian, T.B., Ganz, P.A., Costantino, J.P., Vallow, L.A., Albain, K.S., Wolmark, N., Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) Lancet, 387 (February (10021)), pp. 849-856; McCormick, B., Randomized trial evaluating radiation following surgical excision for “good risk” DCIS: 12-year report from NRG/ RTOG 9804 2018 ASTRO Annual Meeting Late-breaking Abstract Selection (2019) Int. J. Radiat. Oncol. Biol. Phys., 102 (November (3) (Supplement)); McCormick, B., Winter, K., Hudis, C., Kuerer, H.M., Rakovitch, E., Smith, B.L., Sneige, N., White, J., RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation (2015) J. Clin. Oncol., 33 (March (7)), pp. 709-715; Meattini, I., Lambertini, M., Isacco, D., De Caluwé, A., Kaidar-Person, O., Lorenzo, L.L., Radiation therapy for young women with early breast cancer: current state of the art (2019) Crit. Rev. Oncol. Hematol., p. 137; Montero, A., Sanz, X., Hernanz, R., Cabrera, D., Arenas, M., Bayo, E., Moreno, F., Algara, M., Accelerated hypofractionated breast radiotherapy: FAQs (frequently asked questions) and facts (2014) Breast, 23 (August (4)), pp. 299-309; Pesce, C.E., Liederbach, E., Czechura, T., Winchester, D.J., Yao, K., Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base (2014) J. Am. Coll. Surg., 219 (July (1)), pp. 19-28; Rakovitch, E., Nofech-Mozes, S., Hanna, W., Sutradhar, R., Gu, S., Fong, C., Tuck, A., Paszat, L., Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy (2018) Breast, 37 (February), pp. 181-186; Rashtian, A., Iganej, S., Amy Liu, I.L., Natarajan, S., Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy (2008) Int. J. Radiat. Oncol. Biol. Phys., 72 (November (4)), pp. 1016-1020; Rutter, C.E., Park, H.S., Killelea, B.K., Evans, S.B., Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the United States (2015) Ann. Surg. Oncol., 22 (July (7)), pp. 2378-2386; Shah, C., Vicini, F.A., Berry, S., Julian, T.B., Wilkinson, J.B., Shaitelman, S.F., Khan, A., Goldstein, N., Ductal carcinoma in situ of the breast: evaluating the role of radiation therapy in the management and attempts to identify low-risk patients (2015) Am. J. Clin. Oncol., 38 (October (5)), pp. 526-533; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2018 (2018) CA Cancer J. Clin., 68 (Jane (1)), pp. 7-30; Solin, L.J., Gray, R., Hughes, L.L., Wood, W.C., Lowen, M.A., Badve, S.S., Baehner, F.L., Davidson, N.E., Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study (2015) J. Clin. Oncol., 33 (November (33)), pp. 3938-3944; Staley, H., McCallum, I., Bruce, J., Postoperative tamoxifen for ductal carcinoma in situ: cochrane systematic review and meta-analysis (2014) Breast, 23 (October (5)), pp. 546-551; START Trialists’ Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Bentzen, S.M., Yarnold, J.R., The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial (2008) Lancet, 371 (March (9618)), pp. 1098-1107; START Trialists’ Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Bliss, J.M., Yarnold, J.R., The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial (2008) Lancet Oncol., 9 (April (4)), pp. 331-341; Strach, M.C., Prasanna, T., Kirova, Y.M., Alran, S., O'Toole, S., Beith, J.M., Poortmans, P., Carroll, S., Optimise not compromise: the importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery (2019) Crit. Rev. Oncol. Hematol., 134 (February), pp. 10-21; Timbrell, S., Al-Himdani, S., Shaw, O., Tan, K., Morris, J., Bundred, N., Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with ductal carcinoma in situ (2017) Ann. Surg. Oncol., 24 (April (4)), pp. 1071-1076; Tsang, Y., Haviland, J., Venables, K., Yarnold, J., FTM Group, The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy (2012) Radiother. Oncol., 104, pp. 143-147; Vargas, C., Kestin, L., Go, N., Krauss, D., Chen, P., Goldstein, N., Martinez, A., Vicini, F.A., Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy (2005) Int. J. Radiat. Oncol. Biol. Phys., 63 (December (5)), pp. 1514-1521; Wai, E.S., Lesperance, M.L., Alexander, C.S., Truong, P.T., Culp, M., Moccia, P., Lindquist, J.F., Olivotto, I.A., Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ (2011) Cancer, 117 (January (1)), pp. 54-62; Wapnir, I.L., Dignam, J.J., Fisher, B., Mamounas, E.P., Anderson, S.J., Julian, T.B., Land, S.R., Wolmark, N., Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS (2011) J. Natl. Cancer Inst., 103 (March (6)), pp. 478-488; Wärnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., Ringberg, A., Holmberg, L., Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial (2014) J. Clin. Oncol., 32 (November (32)), pp. 3613-3618; Whelan, T.J., Pignol, J.P., Levine, M.N., Julian, J.A., MacKenzie, R., Parpia, S., Shelley, W., Freeman, C., Long-term results of hypofractionated radiation therapy for breast cancer (2010) N. Engl. J. Med., 362 (February (6)), pp. 513-520; Williamson, D., Dinniwell, R., Fung, S., Pintilie, M., Done, S.J., Fyles, A.W., Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ (2010) Radiother. Oncol., 95 (June (3)), pp. 317-320. , doi: 0.1016/j.radonc.2010.03.021; Zhao, H., Hei, N., Wu, Y., Chan, W., Lei, X., Cameron, C., Chang, S., Giordano, S.H., Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ (2017) Cancer, 123 (May (6)), pp. 940-947

PY - 2019

Y1 - 2019

N2 - Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second “Assisi Think Tank Meeting” (ATTM) on Breast Cancer. Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5–20 years work-experience and irradiated 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated. © 2019 Elsevier B.V.

AB - Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second “Assisi Think Tank Meeting” (ATTM) on Breast Cancer. Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5–20 years work-experience and irradiated 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated. © 2019 Elsevier B.V.

KW - Breast cancer

KW - Ductal carcinoma in situ

KW - Hypofractionation

KW - Post-mastectomy radiotherapy

KW - Survey

KW - estrogen receptor

KW - Ki 67 antigen

KW - progesterone receptor

KW - tamoxifen

KW - age

KW - breast radiotherapy

KW - breast reconstruction

KW - cancer grading

KW - human

KW - hypofractionated radiotherapy

KW - immunohistochemistry

KW - intensity modulated radiation therapy

KW - intraductal carcinoma

KW - mastectomy

KW - nipple sparing mastectomy

KW - postmastectomy radiation therapy

KW - radiation oncologist

KW - Review

KW - skin sparing mastectomy

KW - surgical margin

KW - surgical technique

KW - tomotherapy

KW - tumor volume

KW - adjuvant radiotherapy

KW - breast tumor

KW - female

KW - middle aged

KW - prevention and control

KW - procedures

KW - questionnaire

KW - radiation oncology

KW - risk factor

KW - tumor recurrence

KW - Breast Neoplasms

KW - Carcinoma, Intraductal, Noninfiltrating

KW - Dose Fractionation, Radiation

KW - Female

KW - Humans

KW - Mastectomy

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Radiation Oncology

KW - Radiotherapy, Adjuvant

KW - Risk Factors

KW - Surveys and Questionnaires

U2 - 10.1016/j.critrevonc.2019.04.016

DO - 10.1016/j.critrevonc.2019.04.016

M3 - Article

VL - 138

SP - 207

EP - 213

JO - Crit. Rev. Oncol. Hematol.

JF - Crit. Rev. Oncol. Hematol.

SN - 1879-0461

ER -